Mira-55 shows morphine-comparable pain relief in animal model; SKNY acquisition clears SEC review

MIRA PHARMACEUTICALS, INC.

Mira-55, a non-psychoactive marijuana analog, matched morphine's pain relief in a formalin-based rodent model without sedation or inflammation.
DEA previously confirmed Mira-55 is not a controlled substance, removing a key regulatory barrier to clinical development.
SEC completed review of merger proxy for SKNY Pharmaceuticals acquisition with no comments, enabling shareholder vote.
SKNY-1, the target therapy, demonstrated 30% body weight reduction without muscle loss and reversal of nicotine cravings in recent studies.
MIRA advancing Mira-55 toward IND submission for inflammatory pain indications.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.